Eli Lilly announces $6.5B manufacturing plant in Houston, boosting investment from initial proposal
The $6.5 billion Houston facility will create 615 permanent jobs and 4,000 construction jobs while producing orforglipron and other small molecule drugs to reduce foreign API dependence.
- Eli Lilly plans to build a new $6.5 billion manufacturing facility for small molecule drugs in Houston, Texas.
- The facility will focus on producing Eli Lilly's potential obesity and diabetes drug orforglipron and create 615 new jobs in the area.
- Construction on the 236-acre site is expected to begin this year and be completed within 5 years, generating around 4,000 construction jobs.
48 Articles
48 Articles
Eli Lilly announces second major investment in US manufacturing
The pharmaceutical company Eli Lilly announced on Tuesday that it will build a $6.5 billion facility in Texas, marking the company’s second multibillion-dollar U.S. investment this month. The Indiana-based company announced in February that it would be making four distinct manufacturing investments in 2025 across the United States, with the goal of bringing 13,000 domestic jobs to the American economy. Eli Lilly recently announced the first of t…
Pharmaceutical giant Eli Lilly to invest over $6 billion in Houston
It looks like Eli Lilly is setting up a major investment in Houston. Eli Lilly and Co. confirmed Sept. 23 that the Bayou City will be part of its domestic manufacturing push. David Ricks, Lilly’s CEO and chairman, joined Texas Gov. Greg Abbott to officially announce that the pharmaceutical giant will build a $6.5 billion manufacturing plant in the Generation Park development. In recent years, Eli Lilly has focused heavily on expanding its portfo…
Eli Lilly to Construct $6.5 Billion Manufacturing Facility in Houston
Pharmaceutical giant Eli Lilly and Company has announced plans to build a $6.5 billion manufacturing facility in Houston and is expected to create more than 4,600 manufacturing and construction jobs. Construction at the city’s Generation Park is slated to begin in 2026 and become fully operational by 2031. In a Sept. 23 statement, Lilly revealed it will be manufacturing next-generation synthetic medicine active pharmaceutical products at the Hou…
Coverage Details
Bias Distribution
- 77% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
